REGN · News · 20260808N

Capital Return Program

REGENERON PHARMACEUTICALS, INC. · 2026-08-08 · Importance 10 · Surprise 6

Regeneron confirmed its quarterly dividend following the release of Q2 and first-half 2026 results. The company also provided an update on share repurchases, although the digest did not specify the repurchase amount or remaining authorization. The capital-return activity occurred alongside continued R&D investment in immunology, oncology, genetic medicines, and obesity programs. Investor attention remains focused on balancing buybacks and dividends with pipeline spending and EYLEA competition.

Key facts

• Regeneron confirmed a quarterly dividend and updated on share repurchases in connection with its Q2 and H1 2026 results. source